Latest Investment Opportunities News

Alternative Investment Trust (AIQ) has announced a non-renounceable rights issue to raise approximately $44.6 million at a 19.4% discount, aiming to capitalize on discounted secondary market funds amid liquidity challenges.

Alternative Investment Trust (AIQ) has announced a 1-for-1 non-renounceable rights issue at $1.47 per unit, aiming to raise capital for ongoing investments and increase annual distributions to 10% of adjusted net tangible assets starting early 2026.

Fat Prophets Global Contrarian Fund Limited invites eligible shareholders to participate in a $30 million Share Purchase Plan aimed at strengthening capital and enhancing liquidity without brokerage fees.

Temple & Webster has reported a robust 21% revenue increase in FY25, alongside a near sixfold jump in net profit, setting a confident tone for FY26 with strong early trading and an optimistic outlook.

Arena REIT reported a robust 17% increase in net operating profit for FY2025, underpinned by strong portfolio management and development activity, while raising its distribution guidance by 5.5% for FY2026.

PM Capital Global Opportunities Fund Limited reported a robust 33.98% rise in profit after tax to $168.2 million for FY25, alongside a raised fully franked final dividend of 6.0 cents per share. The fund’s portfolio outperformed key benchmarks, reflecting strategic positioning amid structural global economic changes.

Magnetite Mines Limited has updated its Razorback Iron Ore Project, revealing a 6.6 billion tonne mineral resource and progressing key strategic partnerships and approvals to support green steelmaking ambitions.

Story-i Limited reported a significantly reduced half-year loss of $386,949 for December 2024, down from nearly $24 million a year earlier, as it exits its Indonesian operations and focuses on recapitalisation and new investments.

Washington H. Soul Pattinson reports a solid FY25 with rising net asset value and a 27th consecutive dividend increase, outperforming market benchmarks despite volatility.

Omni Bridgeway Limited has reported record investment proceeds of A$555.5 million for FY25, underpinned by robust completions and a growing pipeline. Positive regulatory shifts in key markets further bolster the company’s outlook.

Assetora Limited has strengthened its financial footing with over two quarters of funding and secured a pivotal role as Responsible Entity of the DomaCom Fund, alongside a strategic $700 million mortgage management agreement.

Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.